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Abstract  
Background and Purpose-Translational research is beginning to reveal the importance 
of trophic factors as a therapy for cellular brain repair. The purpose of this study was to 
analyze whether brain-derived neurotrophic factor (BDNF) administration could 
mediate oligodendrogenesis and remyelination after white matter injury in subcortical 
stroke.  
Methods-Ischemia was induced in rats by injection of endothelin-1. At 24h, 0.4µg/kg of 
BDNF or saline was intravenously administered to the treatment and control groups, 
respectively. Functional evaluation, magnetic resonance imaging (MRI) and fiber tract 
integrity on tractography images were analyzed. Proliferation (KI-67) and white matter 
repair markers (A2B5, CNPase, APC, PDGFR-alpha, O4,Olig-2 and MBP) were 
analyzed at 7d and 28d. 
Results-The BDNF-treated animals showed less functional deficit at 28d after treatment 
than the controls (p<.05). Although T2-MRI did not show differences in lesion size at 
7d and 28d between groups, diffusion tensor imaging (DTI) tractography analysis 
revealed significantly better tract connectivity at 28d in the BDNF group than in the 
controls (p<.05). Increased proliferation of oligodendrocyte progenitors was observed in 
treated animals at 7d (p<.05). Finally, the levels of white matter repair markers (A2B5, 
CNPase, O4 at 7d; Olig-2, MBP at 28d) were higher in the BDNF group than in the 
controls (p<.05).  
Conclusions-BDNF administration exerted better functional outcome, 
oligodendrogenesis, remyelination and fiber connectivity than controls in rats subjected 
to subcortical damage in ischemic stroke. 
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Background 
After decades of research focused on the search for a treatment for cortical infarcts in 
experimental models in which the gray matter is most affected, a few translational 
studies are beginning to highlight the importance of considering the white matter 
component after stroke.1 Not only are up to 25% of ischemic strokes in humans 
subcortical or lacunar and confined to white matter regions2 but cortical infarcts also 
produce white matter injury. The high frequency of this damage motivates the search for 
an effective therapy to enhance the mechanisms underlying the repair of damaged white 
matter (axons and myelin) after a stroke.2  
Trophic factors are emerging as a viable repair therapy in stroke, and they can strongly 
promote a favorable environment for cellular repair after brain injury.3,4 One of the 
prominent trophic molecules is brain-derived neurotrophic factor (BDNF), which is 
secreted in an activity-dependent manner and crucially promotes synaptic regulation and 
axonal plasticity associated with learning, memory and sensorimotor recovery.4,5 
Furthermore, in vitro and BDNF knock-out studies have demonstrated that this trophic 
factor has direct effects on oligodendroglia, promoting the proliferation and 
differentiation of oligodendrocyte precursor cells (OPC) and myelination.6-8  
All of the above indicate that BDNF could exert a possible effect upon 
oligodendrogenesis and remyelination after a stroke. Thus, the present study explored 
the possible effect of BDNF administration on white matter remodeling via 
oligodendrogenesis and myelinogenesis and whether this effect might correlate with 
functional recovery in an animal model of subcortical stroke. 
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Materials and Methods  
Study design 
This translational study followed all STAIR (stroke therapy academic industry 
roundtable) and RIGOR guidelines in terms of randomization, blinding and statistical 
power.9 In addition, the experiments were designed to minimize animal suffering in 
compliance with our medical school’s Ethical Committee for the Care and Use of 
Animals in Research (EU directives 86/609/CEE and 2003/65/CE). A total of 74 adult 
Sprague-Dawley rats (200 to 250g) were randomly distributed into 3 groups: Sham: 
surgery without endothelin-1 (ET-1) injection + IV saline administration (n=24); 
Control: subcortical stroke + IV saline administration (n=24); and BDNF animals: 
subcortical stroke + IV BDNF treatment (n=24). In the BDNF group, recombinant 
human BDNF (Peprotech,UK) was diluted in saline to a final volume of 1mL and 
administered through the tail vein at a final dose of 0.4µg/kg at 24h after surgery. A 
saline solution of the same volume was delivered to the control and sham animals. The 
rats were then randomly divided into 3 subgroups that were euthanized at 4h (n=4/each 
group), at 7d (n=10/each group) or at 28d (n=10/each group). Two rats were excluded 
from the study because one died after surgery and the other died during the magnetic 
resonance procedure.  
ET-1 subcortical stroke model 
In all the animals, physiological parameters and body temperature were continuously 
monitored during surgery (Online-only Data Supplement). To provoke white matter 
injury, a subcortical stroke was induced to pre-anesthetized rats following a small 
craniotomy by the injection of a potent vasoconstrictor, endothelin-1, using a 
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stereotactic apparatus employing stereotactic references (+0.4mmAP, +3.5mmL, 
+6mmDV from the bregma). 1µL of ET-1 (0.25ug/µL) was delivered at a final speed of 
0.2µL/m. Immediately after surgery, analgesia was provided to all groups by an 
intraperitoneal injection of meloxicam at 2mg/Kg.  
BDNF quantification after treatment  
BDNF was quantified by the human BDNF ELISA kit (ABCAM) and Western blot in 
brain tissue and serum in both the control and treated animals at 4h, 7 and 28d (Online-
only Data Supplement). Immunofluorescence (using a primary antibody anti-BDNF 
[1:1000, Millipore] and a secondary antibody anti-rabbit Alexa Fluor 594 [1:750, 
Invitrogen]) (n=4 per group). 
Functional evaluation scales 
Functional evaluation was scored in all animals by a blinded observer before surgery 
and at 1, 3, 7 and 28d after treatment. Motor performance evaluation was measured by 
beam walking test,10 the rotarod test11 and the Modified Rogers Scale12 (Online-only 
Data Supplement).  
In vivo analysis by MRI and DTI tractography 
To analyze whether the BDNF effect could be examined with in vivo imaging 
techniques, we studied the ipsilateral hemisphere at the site of the ET-1-induced lesion 
using T2-MRI, diffusion on ADC maps and tract connectivity using DTI tractography 
(n=6 of each group) at 7 and 28d after treatment (Online-only Data Supplement).  
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Cell proliferation analysis 
KI-67 staining was analyzed on days 7 and 28, using 10 sections selected from each 
animal (n=6 animals per group) (Online-only Data Supplement).  
To evaluate differentiation markers in proliferating cells, we double stained KI-67-
positive cells with CNPase, A2B5, APC and PDGFR-alpha by immunofluorescence. All 
the images were acquired as a maximum confocal projection.  
Immunohistochemistry, immunofluorescence and Western blot 
CryoMyelin staining kit (Hito Biotech) that allows sensitive localization and 
visualization of the myelin fibers was performed on frozen sections. The mean region of 
interest (ROI) intensity in the CryoMyelin staining was quantified using a Nikon 
Eclipse-Ti inverted microscope and NIS-elements software. The lesion zone was 
studied in more detail using immunofluorescence and Western blot as previously 
described (n=4 animals of each group).11  CNPase, A2B5, O4, Nogo-A, MBP and Olig-
2 markers were studied at 7 and 28d (Online-only Data Supplement).  
Statistical analysis 
The data are presented as mean±standard error of the mean (SEM). The Kruskal-
Wallis test followed by the Mann-Whitney U test was used to compare data. Values of 
p<.05 were considered significant at a 95% confidence interval (CI); the data were 
calculated using statistical software programs SPSS 16 and GraphPad. 
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Results 
BDNF levels were increased after treatment 
ELISA analysis of serum BDNF showed that the levels were augmented at 4h after its 
intravenous administration (4.33±0.32; 5.61±0.62; p<.05) (Fig. 1A). BDNF was 
analyzed in the BDNF-treated group and in the control animals throughout the brain. At 
4h, significant higher levels of BDNF were found in the area of injury in BDNF animals 
(6.67±0.43) compared with the controls (0.79±0.24) (p<.05). Also Western blot analysis 
detected higher levels of BDNF in the ischemic lesion in the treated animals 
(0.97±0.08) compared with the control group (0.79±0.24) at 4h after treatment (p<.05). 
At 7 and 28d after administration, the BDNF levels were not significantly different in 
the treated animals (0.28±0.03 and 0.20±0.08) compared with the control group 
(0.27±0.063 and 0.204±0.049), respectively (Fig.1B,1C). Immunofluorescence for 
BDNF showed both intracellular and extracellular staining (Fig.1C). 
BDNF improved functional recovery in the subcortical white matter injury model 
No significant differences were found in the functional outcome of the treated and 
control animals at 1, 3 and 7d after treatment. However, compared with the control rats, 
28d after treatment the BDNF treated rats showed significantly better rotarod test 
performances (67.25±25.10 and 103.00±16.10, respectively; p=.049), beam walking 
(3.5±0.70 and 1.4±0.54, respectively; p=.042) and Modified Rogers Test (2.5±0.57 and 
1.2±0.44, respectively; p=.018) (Fig.2A).  
 
 
7 
 
BDNF effects on white matter were negligible by in vivo MRI but perceptible by 
tractography and myelin staining 
The lesion size viewed on MRI in the BDNF-treated animals was indistinguishable 
from the control group at 7d (7.30±2.56 and 14.75±1.72, respectively) and 28d 
(7.49±1.79 and 8.77±3.97, respectively) after treatment (p>.05) (Fig.2C). 
DTI tractography data showed similar results in axial diffusivity (124.297±10.72 and 
133.73±14.497; p>.05) and diffusion in ADC maps (93.58±10.033 and 123.307±23.839; 
p>.05) in both the control and treated groups, respectively, at 7d after stroke. However, 
compared with the control rats, 28d after treatment the BDNF-treated rats showed 
significantly improved axial diffusivity (126.39±7.82 and 159.715±14.761, respectively; 
p<.05) and diffusion in ADC maps (129.743±11.934 and 157.926±12.562, respectively; 
p<.05) (Fig.2C). This result suggests that there was a significant improvement in white 
matter thickness (width, breadth, depth) and restoration of tract connectivity in the 
BDNF-treated animals compared with controls at 28d. 
These results are in agreement with the morphological study of myelin fibers by 
CryoMyelin staining. The mean ROI intensity was calculated at the lesion site in the 
control and BDNF-treated animals, in which white intensity indicated absence of 
myelin and black intensity the presence of myelinated axons. The results showed higher 
intensity (absence of axons) in controls (198.61±26.30) compared with BDNF-treated 
animals (172.18 ±17.40) (Fig.2B).  
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BDNF administration enhances OPC proliferation after white matter injury 
Numerous KI-67-positive cells were observed in the ischemic lesion in the control 
animals and in the BDNF-treated group. The number of KI-67-positive cells 
(170±17.32) was significantly higher in the ischemic lesion compared with control 
group (34.25±18.28) (p=.032) 7d after BDNF treatment (Fig.3A). 
Double staining of KI-67-positive cells with the OPC markers was observed to be 
higher in the subventricular zone in treated animals than in controls for A2B5 
(9.12±1.87% and 5.45±2.10%), CNPase (31.00±7.32% and 22.12±5.34%), APC 
(26.00±5.12% and 17.32±4.21%) and PDGFR-alpha (36.00±6.23% and 28.00±7.34%), 
suggesting that OPC proliferation is enhanced after BDNF injection (Fig.3B).  
BDNF injection increases OPC markers 7d after axonal disruption 
The levels of OPC markers were analyzed by Western blot in the lesion area at 7 and 
28d after treatment (Fig.4B). There was a significant increase in CNPase marker levels 
in the BDNF-treated animals (217.00±14.10) compared with the controls at 7d 
(183.20±16.32) (p<.05). A2B5 was also higher in the BDNF-treated animals 
(141.20±41.20) than in the controls (75.39±13.20) at 7d after treatment (p<.05). We also 
found higher levels O4 marker at 7d, in the BDNF-treated group (190.88±20.19) than in 
the control animals (82.10±18.01; p<.05). At 28d the levels of OPC markers were lower 
in both control and BDNF animals. Also, when comparing treated and control groups at 
28d, no significant differences were found (A2B5 [91.12±41.10 vs 112.10±13.81], 
CNPase [89.23±21.10 vs 110.10±21.30] and O4 [75.20±19.10 vs 69.60±16.13] 
respectively). IHF analysis confirmed these results (Fig.4A). 
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BDNF administration enhances oligodendrocyte maturation and axonal growth-
associated markers 28d post injury 
At 7 and 28d we analyzed markers related to later developmental steps in white matter 
differentiation (MBP, Olig-2) and in maturation of myelin fibers (Nogo-A) (Fig.5A,5B). 
Western blot analysis showed significantly higher levels of the oligodendrocyte 
marker Olig-2 in the BDNF-treated animals than in the control group at 28d 
(242.85±15.50 and 94.21±10.20, respectively; p<.05) and a significant increase in MBP 
in the treated animals compared with the controls (192.18±29.99 and 106.55±26.74, 
respectively; p<.0.05). We also found a significant decrease in Nogo-A levels in the 
BDNF-treated animals compared with the controls at 7d (160.11±17.23 and 
213.21±12.41 respectively) and at 28d (163.01±18.88 and 200.10±9.87, respectively; 
p=.014). At 7d the levels of Olig-2 (150.25±19.43 and 70.91±21.50) and MBP 
(51.21±23.10 and 25.01±10.80) were too low compared with 28d in both the treated 
group and control group because all these markers are related to later developmental 
steps in white matter differentiation.  
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Discussion 
In the current search for new therapeutic strategies to improve functional and cognitive 
deficits after stroke, it is worth remembering that myelination failure prevention is 
necessary for brain repair processes. Thus, the present study employed an intravenous 
infusion (0.4µg/kg) of BDNF as a therapeutic strategy to prevent myelination failure. 
The group treated with BDNF injection showed improved functional recovery and a 
significant increase in the number of proliferating cells, including OPC, after white 
matter injury. After using BDNF, large numbers of cells expressed OPC markers such 
as CNPase, A2B5 and O4 at 7d. At 28d after treatment, the cells began to acquire 
specific markers of oligodendrocyte differentiation, such as Olig-2 and MBP, 
suggesting that repair of white matter fiber tracts was induced by the BDNF injection. 
The results support a role for BDNF in improving the repair of white matter and in OPC 
proliferation and differentiation in this experimental subcortical stroke model. 
This treatment was chosen because systemic administration is already known to allow 
BDNF to cross the blood brain barrier.4,13 In this sense, the BDNF levels in our study 
were augmented in brain tissue and peripheral serum at 4h after injection. This increase 
of BDNF levels observed in the brain might enhance recovery mechanisms after stroke. 
BDNF as therapy to induce brain protection and brain repair is becoming more 
common in translational research. After a cortical stroke, BDNF has been shown to 
control neuronal circuits, increase the number of newborn neurons in several brain 
areas,3,4 reduce astrogliosis, enhance axonal growth in the ischemic border zone5 and 
stimulate the plasticity of dendritic branching and synaptic transmission.14 However, the 
effects of BDNF administration on nerve fiber repair, myelin formation and remodeling 
after white matter injury are still unknown. 
11 
 
In a translational study it is important to analyze whether BDNF injections act on the 
motor dysfunctions that are characteristic to subcortical stroke. Previous authors found 
the beam walking test,10 the rotarod test11 and the Modified Rogers Test12 to be effective 
in assessing the motor deficit associated primarily with subcortical stroke. In this study, 
BDNF treatment induced a significant improvement in functional recovery that was 
particularly notable at 28d after treatment compared with the controls. These results 
clearly suggest a true recovery-enhancing effect for BDNF. Although there are no 
previous studies that have administered BDNF in a subcortical stroke model, our results 
are consistent with previous data showing a better functional outcome in animals treated 
intravenously with BDNF after cortical ischemia.4  
 Focal injection of the vasoconstrictor ET-1 into the subcortical white matter produces 
a visible infarct on MRI, as previously shown in subcortical stroke studies.15,16 To 
analyze whether the BDNF effect could be visualized with in vivo imaging techniques, 
we performed T2-MRI, ADC maps and DTI tractography. No significant differences in 
lesion size were observed in the BDNF-treated animals compared with the control 
group on the T2-MRI images; however, analyzing fiber tract integrity by DTI 
tractography showed that tract thickness was recovered at 28d after BDNF 
administration. This result suggests that functional recovery at 28d could be related to 
the process by which restructured axons, which had previously been compromised and 
demyelinated, recover not only their proper structure but also tract connectivity. The 
lack of a relationship between the T2-MRI and DTI tractography images, however, 
remains unclear. This is why we intensified the histological analysis of the injured 
tissue in this study.  
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After a stroke, myelin injury activates the OPC distributed throughout the white 
matter, which proliferate and migrate to the site of damage where they subsequently 
mature into myelinating oligodendrocytes that ensheath axons to form the myelin 
membrane.1,17 Our study using colocalization of the KI-67 antigen and the CNPase, 
A2B5, APC and PDGFR-alpha markers showed BDNF to be a potent factor for 
enhancing the OPC proliferation response after white matter injury. Our findings agree 
with other non-stroke studies in vitro and in BDNF knock-out mice, showing that 
BDNF exerts direct effects upon oligodendroglia, promoting OPC proliferation and 
differentiation, as well as myelination.6-8 To elucidate whether BDNF administration 
also acts on oligodendrocytes and shattered white matter fibers and increases some 
repair mechanisms, including nerve fiber remodeling, axonal sprouting, 
oligodendrogenesis and myelinogenesis, we measured white matter repair-associated 
markers in both the treated and the control animals. Various white matter repair markers 
were studied at two different time points, 7d and 28d. Related to the first steps of the 
genesis and migration of white matter progenitor cells, markers such as A2B5 (a 
characteristic OPC marker), O4 and CNPase (markers related to immature 
oligodendrocytes), were studied in the lesion area. Markers related to white matter 
differentiation and myelin fiber maturation such as MBP (myelin marker), Olig-2 
(mature oligodendrocytes) and the myelin inhibitor Nogo-A were also analyzed.  
The best-characterized oligodendroglial progenitor marker is A2B5.18,19 This molecule 
is a cell surface ganglioside expressed on developing oligodendroglial progenitors. In 
our study, the levels of the A2B5 marker were higher in the BDNF-treated animals at 7d 
than in the control group. O4 is another marker expressed in pro-oligodendrocytes 
during oligodendrocyte differentiation.20 Our study found an increase in the amount of 
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O4 protein in the animals subjected to BDNF administration compared with their 
controls. This observation agrees with a study describing the levels of CNPase.19 The 
presence of CNPase appears to be one of the earliest events in oligodendrocyte 
differentiation and BDNF-treated animals showed higher levels of this marker than the 
control group. The levels of A2B5, CNPase and O4 were too low at 28d because all 
these markers are related to early events in oligodendrocyte differentiation. These 
results are in line with previous non-stroke in vitro studies in which the effects of BDNF 
are examined in oligodendrocyte progenitors, finding enhanced A2B5 and O4 
expression after neurotrophin administration.21  
Regarding the oligodendrocyte maturation-associated proteins, the levels of these 
markers were found to be too low at 7d. However, Olig-2 levels were elevated in the 
treated animals compared with the control animals at 28d, an observation that could be 
explained by BDNF having enhanced oligodendroglial cell differentiation. However, 
both the presence of mature oligodendrocytes and coating the myelin sheath are 
important for white matter repair. There was a significant increase of MBP reactivity in 
the white matter tracts at 28d in the treated animals compared with the control group. 
Although there are no previous studies that relate BDNF to remyelination after stroke, 
these increases in the levels of MBP and Olig-2 concur quite well with previous 
nonstroke studies indicating that BDNF influences differentiating oligodendrocytes by 
increasing both the number of MBP cells and the expression of the MBP protein.22 
What is unknown is whether the increased myelination was because more axons were 
being myelinated or whether there was an overall increase in myelin thickness. 
Among the myelin-associated proteins, Nogo-A has been shown to be particularly 
powerful in preventing axonal growth and plasticity.23 Nogo-A not only inhibits axonal 
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growth, but also prevents neurotrophins such as BDNF from binding to this receptor 
inhibiting axonal growth.24 Some studies have demonstrated that inhibition mediated by 
Nogo-A is blocked if neurons are exposed to BDNF before encountering the inhibitor.25 
The present study concurs with these observations because at 28d after treatment there 
was a significant decrease in the levels of Nogo-A in BDNF animals. These results 
indicate that BDNF injection could enhance axonal growth and plasticity by decreasing 
Nogo-A levels. The observations found at 28d suggest that functional recovery might be 
related to the axonal sprouting subsequent to BDNF administration, and could be 
indicative of the process by which growing and as-yet demyelinated axons are re-
covered with new myelin sheaths. Furthermore, this interpretation of these observations 
agrees with the tractography images that suggest that tract connectivity was being 
restored in the infarcted area at the same time point. 
Conclusions 
Our study helped us to identify a clear role for BDNF in improving functional outcome 
by mediating axonal growth, OPC proliferation, oligodendrocyte differentiation, 
remyelination and fiber tract connectivity restoration in an experimental animal model 
of white matter injury.  
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Figure legends  
Figure 1. BDNF levels in the brain and peripheral serum are augmented at 4h after 
systemic BDNF administration returning to lower levels at 7 and 28d.  (A). ELISA (B). 
Western blot and (C) Immunofluorescence (IHF) (Data are mean ± SEM, scale bars=20 
µm; *=p<.05, 4 animals, 4 sections each per group in IHF). 
 Figure 2. Improved functional recovery and connectivity in BDNF treated animals. 
(A) beam walking test (left), rotarod test (middle) and Modified Rogers Test (right). 
(B). Morphological study by CryoMyelin staining identified the zone of the lesion as an 
area of white matter injury located in the subcortical zone, showing restored myelinated 
axons in the BDNF-treated animals. Quantification of mean ROI intensity of the 
CryoMyelin staining Stroked line indicates ROI; Yellow line indicates a representative 
longitudinal profile of pixel intensity. (C) Qualitative and quantitative analysis of T2-
weighted MRI (left), axial diffusivity in DTI tractography (center) and diffusion in 
ADC images (right) at 28d showed a significant progressive reduction in white matter 
injury, showing augmented connectivity of the fiber tracts in the BDNF-treated animals 
compared with the control group. Zoomed lesion site 3D views of DTI tractography 
images are shown (Data are mean ± SEM, scale bars=20 µm, *=p<.05, 6 animals, 10 
sections each per group). 
Figure 3. Aumented cell proliferation after BDNF treatment at 7d. (A) Qualitative and 
quantitative analysis of cell proliferation by KI-67 staining. (B) KI-67 co-labeling with 
CNPase, A2B5, APC and PDGFR-alpha markers at 7d after treatment.  (Data are mean 
± SEM, scale bars=20 µm, *=p<.05, 6 animals, 10 sections each per group) 
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Figure 4. Increased OPC-related markers (A2B5, CNPase, O4) at 7d after BDNF 
treatment. At 28d, all these levels were decreased compared with 7d measured by 
immunofluorescence (A) and Western blot (B) (Data are mean ± SEM, scale bars=20 
µm, *=p<.05, 4 animals, 4 sections each per group).  
Figure 5. Increased white matter maturation and axonal growth-associated markers at 
28d (MBP, Olig-2) and decreased levels of Nogo-A after BDNF treatment. (A) 
Immunofluorescence and (B) Western blot (Data are mean ± SEM, scale bars=20 µm, 
*=p<.05, 4 animals, 4 sections each per group).  
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SUPPLEMENTAL MATERIAL 
ET-1 subcortical stroke model 
In all the animals, continuous monitoring of physiological parameters (glycemia, 
blood gases and blood pressure) was performed during surgery and ischemia (Monitor 
Omicron ALTEA RGB medical devices, Madrid, Spain). Body temperature was also 
monitored and maintained at 36.5 ± 0.5°C. All the surgical experiments were performed 
on adult rats that were secured on a stereotactic apparatus under isoflurane inhalatory 
anesthesia. 
  BDNF quantification after treatment  
The BDNF levels were quantified by a human BDNF ELISA kit (ABCAM), Western 
blot and immunohistochemistry in the brain tissue and serum 4h after treatment in both 
the control animals and the treated animals. The BDNF ELISA determination was 
performed according to the manufacturer’s specifications. The standard curves and the 
samples were run in duplicate. The serum was diluted 1:20. For BDNF biodistribution 
analysis in the brain, 40µg of total protein from all the different isolated brain areas 
were added to the different ELISA sample wells. The absorbance was measured at 
450nm with an Epoch microplate spectrophotometer (Bioteck). To analyze BDNF brain 
levels at different times, Western blot and immunofluorescence were performed 4h, 7 
and 28d after injection in the lesion zone, using a primary antibody anti-BDNF (1:1000, 
Millipore) and a secondary antibody anti-rabbit Alexa Fluor 594 (1:750, Invitrogen). 
The slices were examined using a LEICA TCS SPE spectral confocal microscope (Leica 
Microsystems, Heidelberg, Germany) and the confocal images were analyzed using 
LEICA software LAS AF, version 2.0.1 Build 2043. All the images were acquired as a 
maximum confocal projection. For the Western blot, the units were normalized based 
on beta-actin levels (1:400, Sigma-Aldrich). 
Functional evaluation scales 
Functional evaluation was scored by a blinded observer on all the animals before 
surgery and at 1, 3, 7 and 28d after treatment by 3 different tests. First, the beam 
walking test measured the ability of rats to cross a wooden beam (2.5×2.5×80 cm). 
Scores were assigned as follows: score 0, traversed the beam with no foot slip; score 1, 
traversed with grasping of the lateral side of the beam; score 2, showed difficulty 
crawling across the beam but was able to traverse; score 3, required >10 seconds to 
traverse the beam because of difficulty in walking; score 4, unable to traverse the beam; 
score 5, unable to move the body or any limb on the beam; and score 6, unable to stay 
on the beam for >10 seconds. Second, the rotarod test measured the latency to fall from 
a rotating cylinder. Beginning three days before surgery, rats were trained on the 
accelerating (4 to 40 rpm) cylinder consisting of three sessions per day. The time each 
animal remained on the rotarod was measured twice per animal with a 15-minutes 
interval between each trial. The mean of the two trials was calculated. Third, a variant 
of the Modified Rogers Scale consisted of a 7-point behavioral rating scale: score 0, no 
functional deficit; score 1, failure to extend left forepaw fully; score 2, decreased grip of 
the left forelimb while tail gently pulled; score 3, spontaneous movement in all 
directions, contralateral circling only if pulled by the tail; score 4, circling or walking to 
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the left; score 5, walked only when stimulated; score 6, unresponsive to stimulation with 
a depressed level of consciousness; and score 7, dead.  
T2-MRI and DTI tractography 
The BDNF effects were studied with in vivo imaging techniques, using T2-MRI and 
DTI tractography. First, the lesion size was analyzed at 7 and 28d after treatment using 
magnetic resonance imaging (MRI) (Bruker Pharmascan, Ettlingen, Germany, 7 Tesla 
horizontal bore magnets) and T2 maps (RARE 8 T2, 180° flip angle, 3 averages) as 
previously described.1 The lesion area was then expressed as a percentage of the 
contralateral hemisphere, after correcting for brain edema. Second, for diffusion 
analysis, we used ADC maps. Third, for tractography, diffusion tensor data (DTI) were 
acquired at 7 and 28d after treatment with a spin echo single shot echo planar imaging 
(EPI) pulse sequence using the following parameters: TR/TE: 5000/35ms; a signal 
average of 10, a 30 noncolinear diffusion gradient scheme with diffusion weighting of 
b=1000 s/mm2 and b=0 s/mm2, and field of view 3.5x3.5 cm. There were a total of 496 
slices, and the data was acquired using 30 directions. The data were acquired with a 
single shot EPI sequence on a 96x96 matrix, and zero-filled k-space to construct a 
128x128 image matrix. The images were obtained with medInria, a multi-platform 
medical image processing and visualization software. Analysis of ADC and DTI-
tractography data was performed in the lesion zone using n=6 animals per group. 
Zoomed lesion site 3D views of DTI tractography images are represented using 
ParaView 4.1.0 software.   
Cell proliferation analysis 
For the KI-67 staining, tissue slices were placed in a boiled citrate buffer (pH 6) and a 
non-specific binding was blocked for 1h with 3% normal goat serum (Vector 
Laboratories). Ki-67 was used as a primary antibody (1:100, Millipore), and the 
Vectastain Universal Quick Kit PK8800 was used as a secondary antibody (1:100, 
Vector Laboratories). The images were acquired using a 40× objective lens and the total 
number of positive cells were counted in a minimum of 10 different microscope fields 
using image analysis software. 
To study the differentiation of the proliferating cells, we double stained KI-67-positive 
cells (1:100, Millipore) with 2',3'-Cyclic-nucleotide3'-phosphodiesterase (CNPase) 
(1:500, Sigma-Aldrich), A2B5 (1:500, Millipore), APC (CC1) (1:20, Abcam) and 
PDGFR-alpha (1:100, Abcam). The corresponding secondary antibodies were goat anti-
mouse Alexa Fluor 488 and Alexa Fluor 594 (1:750, Invitrogen). The co-stained cells 
were observed using the 40× objective lens with LEICA software LAS AF. All the 
images were acquired as a maximum confocal projection.  
Immunohistochemistry, immunofluorescence and Western blot 
The staining of the myelin and myelinated axons was performed on frozen sections 
using a CryoMyelin kit (Hito Biotech, USA), which allows sensitive localization and 
visualization of the myelin fibers. The lesion zone was studied in more detail using 
immunofluorescence and Western blot, as previously described (n=4 animals of each 
group).1  The different primary antibodies used for immunofluorescence and Western 
blot analysis were CNPase (1:500, Sigma-Aldrich), A2B5 (1:500, Millipore), 
Oligodendrocyte marker-4 (O4) (1:25, Millipore), Nogo-A (1:100, ABCAM), myelin 
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basic protein (MBP) (1:100, ABCAM) and the marker oligodendrocyte marker-2 (Olig-
2) (1:500, Millipore). The secondary antibodies for immunofluorescence were goat anti-
mouse Alexa Fluor 488 and anti-rabbit Alexa Fluor 594 (1:750, Invitrogen). The slices 
were examined using a LEICA TCS SPE spectral confocal microscope (Leica 
Microsystems, Heidelberg, Germany) and the confocal images were analyzed using 
LEICA software LAS AF, version 2.0.1 Build 2043. All the images were acquired as a 
maximum confocal projection. To quantify the levels of brain markers by 
immunofluorescence, the experiments, images and quantification of the control and the 
BDNF samples were performed the same day, with the same microscope configurations 
and by blinded observers to eliminate bias due to background normalization. For the 
Western blot, the units were normalized based on beta-actin levels (1:400, Sigma-
Aldrich). 
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